Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06264232 · ClinicalTrials.gov registry record · NA
AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal
A NA study, sponsored by Carl Zeiss Meditec.
- Completed
- Registry status
- NA
- Development phase
- 284
- Enrollment target
NCT06264232: Completed NA study, sponsored by Carl Zeiss Meditec.
NCT06264232 is a NA study that has completed, run by Carl Zeiss Meditec. The registered enrollment target is 284 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06264232, a NA study, has completed, sponsored by Carl Zeiss Meditec.
- COMPLETED
- Registry status
- NA
- Development phase
- 284 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to demonstrate the safety and effectiveness of the full visual range AT ELANA 841P IOL when used to treat adult patients having cataract surgery. Subjects will be randomly selected to receive a pair of IOLs, either the AT ELANA 841P or CT LUCIA 621P lens design. All patients will undergo surgery in both eyes, and they will receive follow up care for up to 6-months. During this time, all patients will undergo thorough eye exams at every study visit and complete questionnaires about their quality of vision post-surgery.
Primary Outcome
Mean, monocular photopic logMAR best-corrected distance visual acuity (BCDVA) at 4 m for the first implanted eyes, at Month 6 (Visit 4).
Interventions
- DEVICE Cataract Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2024-07-12 |
| Est. Completion | 2025-12-01 |
| Phase | NA |
What the finished NCT06264232 record still lists
NCT06264232 is an interventional study that assigns participants to a tested intervention. The registered 284 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which Cataract Surgery is the first listed.
NCT06264232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06264232 about?
NCT06264232 is a clinical study titled "AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal". The goal of this clinical trial is to demonstrate the safety and effectiveness of the full visual range AT ELANA 841P IOL when used to treat adult patients having cataract surgery. Subjects will be randomly selected to receive a pair of IOLs, either the AT ELANA 841P or CT LUCIA 621P lens design. Al...
What is the current status of trial NCT06264232?
This trial is currently completed. It is a NA study. The enrollment target is 284 participants. The study started on 2024-07-12. Estimated completion is 2025-12-01.
What interventions are being tested in trial NCT06264232?
The interventions under investigation include: Cataract Surgery (DEVICE).
Who is sponsoring clinical trial NCT06264232?
This trial is sponsored by Carl Zeiss Meditec, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06264232's enrollment target sits among peer trials
284 377th of 2000 higher than 1,623 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05263206 · 284 participants · Phase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
- NCT05769218 · 284 participants · NA
PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study
- NCT06856577 · 284 participants · Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
- NCT06963034 · 284 participants · Phase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI